These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10223487)

  • 21. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.
    Magklara A; Scorilas A; Stephan C; Kristiansen GO; Hauptmann S; Jung K; Diamandis EP
    Urology; 2000 Sep; 56(3):527-32. PubMed ID: 10962338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
    Becker C; Noldus J; Diamandis E; Lilja H
    Crit Rev Clin Lab Sci; 2001 Oct; 38(5):357-99. PubMed ID: 11720279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor status of lymph node metastases from prostate cancer.
    Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
    Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
    Shariat SF; Kattan MW; Erdamar S; Nguyen C; Scardino PT; Spencer DM; Wheeler TM; Slawin KM
    J Clin Oncol; 2003 Apr; 21(7):1223-31. PubMed ID: 12663708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.
    Chan TY; Mikolajczyk SD; Lecksell K; Shue MJ; Rittenhouse HG; Partin AW; Epstein JI
    Urology; 2003 Jul; 62(1):177-81. PubMed ID: 12837462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of human glandular kallikrein hK2 from LNCaP cells.
    Grauer LS; Charlesworth MC; Saedi MS; Finlay JA; Liu RS; Kuus-Reichel K; Young CY; Tindall DJ
    J Androl; 1996; 17(4):353-9. PubMed ID: 8889697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of sensitive immunoassays for free and total human glandular kallikrein 2.
    Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K
    Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
    Ylikoski A; Pettersson K; Nurmi J; Irjala K; Karp M; Lilja H; Lövgren T; Nurmi M
    Clin Chem; 2002 Aug; 48(8):1265-71. PubMed ID: 12142383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages.
    Corey E; Arfman EW; Oswin MM; Melchior SW; Tindall DJ; Young CY; Ellis WJ; Vessella RL
    Urology; 1997 Aug; 50(2):184-8. PubMed ID: 9255285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
    Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
    J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
    Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
    Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
    Fisher TL; Nocera M; Willis RA; Turner MJ; Abdul Alim CS; Brown DM; Bourne PA; di Sant'Agnese PA; Messing EM; Lord EM; Frelinger JG
    Prostate; 2002 May; 51(3):153-65. PubMed ID: 11967950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free and total human glandular kallikrein 2 in patients with prostate cancer.
    Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
    Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.
    Black MH; Magklara A; Obiezu CV; Melegos DN; Diamandis EP
    Clin Chem; 1999 Jun; 45(6 Pt 1):790-9. PubMed ID: 10351987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D.
    Hsieh ML; Charlesworth MC; Goodmanson M; Zhang S; Seay T; Klee GG; Tindall DJ; Young CY
    Cancer Res; 1997 Jul; 57(13):2651-6. PubMed ID: 9205072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.